3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase NA
2
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Melanoma
158
Keratosis, Actinic
75
Lymphoma, T-Cell, Cutaneous
36
Skin Neoplasms
27
Mycosis Fungoides
27
Lymphoma, Non-Hodgkin
25
Lymphoma, Mantle-Cell
25
Lymphoma, Large-Cell, Immunoblastic
25
Lymphoma, Large B-Cell, Diffuse
25
Lymphoma, Follicular
25
Leukemia, Lymphocytic, Chronic, B-Cell
25
Hodgkin Disease
25
Sezary Syndrome
24
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Lymphoma, B-Cell, Marginal Zone
24
Burkitt Lymphoma
24
Neoplasms
22
Carcinoma, Basal Cell
22
Neoplasm Metastasis
20
Multiple Myeloma
20
Leukemia, Myeloid, Chronic-Phase
20
Leukemia, Myeloid, Accelerated Phase
20
Leukemia, Hairy Cell
20
Leukemia, Myeloid, Acute
19
Blast Crisis
19
Primary Myelofibrosis
18
Lymphoma
18
Uveal Melanoma
17
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
17
Lymphoma, Large-Cell, Anaplastic
17
Interventions
Methotrexate
1
Brentuximab Vedotin
1
Bexarotene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Primary Cutaneous Anaplastic Large Cell
×
Dermatologic
×
Clear all
NCT01578499
2021-01-05
ALCANZA
Takeda
Phase 3
Completed
131 enrolled
24 charts